BACKGROUND: Prostaglandin-endoperoxide synthase 2 (PTGS2, the HUGO Gene Nomenclature Committee-approved official symbol for cycloxygenase-2, COX-2) and its enzymatic product prostaglandin E2 have critical roles in inflammation and carcinogenesis through the G protein-coupled receptor PTGER2 (EP2). The PTGS2 (COX-2) pathway is a promising target for cancer therapy and chemoprevention. PTGS2 (COX-2) expression in colon cancer has been inversely associated with survival as well as tumoral microsatellite instability (MSI) and the CpG island methylator phenotype (CIMP). However, the prognostic significance of PTGER2 expression or its relationship with MSI, CIMP, LINE-1 hypomethylation, or PTGS2 (COX-2) remains uncertain. METHODS: Using the database of 516 colorectal cancers in two prospective cohort studies with clinical outcome data, we detected PTGER2 overexpression in 169 (33%) tumors by immunohistochemistry. We analyzed MSI using 10 microsatellite markers; CIMP by MethyLight (real-time methylation-specific PCR) on an eight-marker panel [CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1]; BRAF, KRAS, PIK3CA, and methylation in LINE-1 by Pyrosequencing; and CTNNB1 (beta-catenin) and TP53 (p53) by immunohistochemistry. RESULTS: PTGER2 overexpression was positively associated with the mucinous component (P = 0.0016), signet ring cells (P = 0.0024), CIMP-high (P = 0.0023), and MSI-high (P < 0.0001). In multivariate analysis, the significant relationship between PTGER2 and MSI-high persisted (adjusted odds ratio, 2.82; 95% confidence interval, 1.69-4.72; P < 0.0001). PTGER2 was not significantly associated with PTGS2 (COX-2), TP53, or CTNNB1 expression, patient survival, or prognosis. CONCLUSION: PTGER2 overexpression is associated with MSI-high in colorectal cancer. IMPACT: Our data imply potential roles of inflammatory reaction by PTGER2 upregulation in carcinogenic process to MSI-high colorectal cancer.
BACKGROUND:Prostaglandin-endoperoxide synthase 2 (PTGS2, the HUGO Gene Nomenclature Committee-approved official symbol for cycloxygenase-2, COX-2) and its enzymatic product prostaglandin E2 have critical roles in inflammation and carcinogenesis through the G protein-coupled receptor PTGER2 (EP2). The PTGS2 (COX-2) pathway is a promising target for cancer therapy and chemoprevention. PTGS2 (COX-2) expression in colon cancer has been inversely associated with survival as well as tumoral microsatellite instability (MSI) and the CpG island methylator phenotype (CIMP). However, the prognostic significance of PTGER2 expression or its relationship with MSI, CIMP, LINE-1 hypomethylation, or PTGS2 (COX-2) remains uncertain. METHODS: Using the database of 516 colorectal cancers in two prospective cohort studies with clinical outcome data, we detected PTGER2 overexpression in 169 (33%) tumors by immunohistochemistry. We analyzed MSI using 10 microsatellite markers; CIMP by MethyLight (real-time methylation-specific PCR) on an eight-marker panel [CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1]; BRAF, KRAS, PIK3CA, and methylation in LINE-1 by Pyrosequencing; and CTNNB1 (beta-catenin) and TP53 (p53) by immunohistochemistry. RESULTS:PTGER2 overexpression was positively associated with the mucinous component (P = 0.0016), signet ring cells (P = 0.0024), CIMP-high (P = 0.0023), and MSI-high (P < 0.0001). In multivariate analysis, the significant relationship between PTGER2 and MSI-high persisted (adjusted odds ratio, 2.82; 95% confidence interval, 1.69-4.72; P < 0.0001). PTGER2 was not significantly associated with PTGS2 (COX-2), TP53, or CTNNB1 expression, patient survival, or prognosis. CONCLUSION:PTGER2 overexpression is associated with MSI-high in colorectal cancer. IMPACT: Our data imply potential roles of inflammatory reaction by PTGER2 upregulation in carcinogenic process to MSI-high colorectal cancer.
Authors: Dallas R English; Joanne P Young; Julie A Simpson; Mark A Jenkins; Melissa C Southey; Michael D Walsh; Daniel D Buchanan; Melissa A Barker; Andrew M Haydon; Simon G Royce; Aedan Roberts; Susan Parry; John L Hopper; Jeremy J Jass; Graham G Giles Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-07 Impact factor: 4.254
Authors: Michael A McIlhatton; Jessica Tyler; Susan Burkholder; Josef Ruschoff; Basil Rigas; Levy Kopelovich; Richard Fishel Journal: Cancer Res Date: 2007-11-15 Impact factor: 12.701
Authors: Shuji Ogino; Emily E King; Andrew H Beck; Mark E Sherman; Danny A Milner; Edward Giovannucci Journal: Am J Epidemiol Date: 2012-08-30 Impact factor: 4.897
Authors: Alexa J Resler; Karen W Makar; Laura Heath; John Whitton; John D Potter; Elizabeth M Poole; Nina Habermann; Dominique Scherer; David Duggan; Hansong Wang; Noralane M Lindor; Michael N Passarelli; John A Baron; Polly A Newcomb; Loic Le Marchand; Cornelia M Ulrich Journal: Carcinogenesis Date: 2014-06-07 Impact factor: 4.944
Authors: Todd L Edwards; Martha J Shrubsole; Qiuyin Cai; Guoliang Li; Qi Dai; Douglas K Rex; Thomas M Ulbright; Zhenming Fu; Harvey J Murff; Walter Smalley; Reid Ness; Wei Zheng Journal: Cancer Prev Res (Phila) Date: 2012-05-02
Authors: Melissa S Simper; Joyce E Rundhaug; Carol Mikulec; Rebecca Bowen; Jianjun Shen; Yue Lu; Kevin Lin; Inok Surh; Susan M Fischer Journal: Mol Oncol Date: 2014-07-03 Impact factor: 6.603
Authors: Shuji Ogino; Paul Lochhead; Andrew T Chan; Reiko Nishihara; Eunyoung Cho; Brian M Wolpin; Jeffrey A Meyerhardt; Alexander Meissner; Eva S Schernhammer; Charles S Fuchs; Edward Giovannucci Journal: Mod Pathol Date: 2013-01-11 Impact factor: 7.842